Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19

Faruque Pathan,1 Shahjada Selim,2 Md Fariduddin,2 Md Hafizur Rahman,3 SM Ashrafuzzaman,1 Faria Afsana,1 Nazmul Kabir Qureshi,4 Tanjina Hossain,5 M Saifuddin,6 AB Kamrul-Hasan,7 Ahmed Salam Mir8 On behalf of the BES Diabetes and COVID Task Force1Department of Endocrinology, BIRDEM General Hospital, D...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pathan F, Selim S, Fariduddin M, Rahman MH, Ashrafuzzaman SM, Afsana F, Qureshi NK, Hossain T, Saifuddin M, Kamrul-Hasan AB, Mir AS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	covid-19 diabetes mellitus sars cov-2 antidiabetic medications endocrine diseases and covid-19 thyroid disease and covid-19 Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/c2877f5bce11418a913927b1b048f2a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2877f5bce11418a913927b1b048f2a6
record_format	dspace
spelling	oai:doaj.org-article:c2877f5bce11418a913927b1b048f2a62021-12-02T14:44:00ZBangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-191178-7007https://doaj.org/article/c2877f5bce11418a913927b1b048f2a62021-05-01T00:00:00Zhttps://www.dovepress.com/bangladesh-endocrine-society-bes-position-statement-for-management-of--peer-reviewed-fulltext-article-DMSOhttps://doaj.org/toc/1178-7007Faruque Pathan,1 Shahjada Selim,2 Md Fariduddin,2 Md Hafizur Rahman,3 SM Ashrafuzzaman,1 Faria Afsana,1 Nazmul Kabir Qureshi,4 Tanjina Hossain,5 M Saifuddin,6 AB Kamrul-Hasan,7 Ahmed Salam Mir8 On behalf of the BES Diabetes and COVID Task Force1Department of Endocrinology, BIRDEM General Hospital, Dhaka, Bangladesh; 2Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; 3Bangladesh Endocrine Society, Dhaka, Bangladesh; 4National Healthcare Network (NHN) Uttara EC, Dhaka, Bangladesh; 5Department of Endocrinology, Green Life Medical College Hospital, Dhaka, Bangladesh; 6Department of Endocrinology, Dhaka Medical College Hospital, Dhaka, Bangladesh; 7Mymensingh Medical College Hospital, Dhaka, Bangladesh; 8Department of Endocrinology, BIHS General Hospital, Dhaka, BangladeshCorrespondence: Shahjada SelimDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka, 1000, BangladeshEmail selimshahjada@yahoo.comBackground: The year 2020 witnessed a largely unprecedented pandemic of coronavirus disease (COVID-19), caused by SARS COV-2. Many people with COVID-19 have comorbidities, including diabetes, hypertension and cardiovascular diseases, which are significantly associated with worse outcomes. Moreover, COVID-19 itself is allied with deteriorating hyperglycemia. Therefore, Bangladesh Endocrine Society has formulated some practical recommendations for management of diabetes and other endocrine diseases in patients with COVID-19 for use in both primary and specialist care settings.Objective: The objective of the article is to develop a guideline to protect the vulnerable group with utmost preference – the elderly and those with comorbid conditions. Therefore, to ensure the adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.Considering and Monitoring Issues: The risk of a fatal outcome from COVID-19 may be up to 50% higher in patients with diabetes than in non-diabetics.Patients with diabetes and COVID had CFR 7.3– 9.2%, compared with 0.9– 1.4% in patients without comorbidities.Diabetic ketoacidosis may be one of the causes of mortality in COVID-19.There is wide fluctuation of blood glucose in these patients, probably due to irregular diet, reduced exercise, increased glucocorticoids secretion, and use of glucocorticoids.HbA1c should be < 7.0% for the majority of the patients, this target may be relaxed in appropriate clinical settings.More emphasis should be given on day-to-day blood glucose levels. Hypoglycemia (< 3.9 mmol/l) must be avoided.Frequent monitoring of blood glucose is needed in critically ill patients.Conclusion: The fight against COVID-19 has been proven to be a challenging one. Therefore, all healthcare personnel should make the best use of updated knowledge and skills to ensure adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.Keywords: COVID-19, diabetes mellitus, SARS COV-2, antidiabetic medications, endocrine diseases and COVID-19, thyroid disease and COVID-19Pathan FSelim SFariduddin MRahman MHAshrafuzzaman SMAfsana FQureshi NKHossain TSaifuddin MKamrul-Hasan ABMir ASDove Medical Pressarticlecovid-19diabetes mellitussars cov-2antidiabetic medicationsendocrine diseases and covid-19thyroid disease and covid-19Specialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 14, Pp 2217-2228 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	covid-19 diabetes mellitus sars cov-2 antidiabetic medications endocrine diseases and covid-19 thyroid disease and covid-19 Specialties of internal medicine RC581-951
spellingShingle	covid-19 diabetes mellitus sars cov-2 antidiabetic medications endocrine diseases and covid-19 thyroid disease and covid-19 Specialties of internal medicine RC581-951 Pathan F Selim S Fariduddin M Rahman MH Ashrafuzzaman SM Afsana F Qureshi NK Hossain T Saifuddin M Kamrul-Hasan AB Mir AS Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
description	Faruque Pathan,1 Shahjada Selim,2 Md Fariduddin,2 Md Hafizur Rahman,3 SM Ashrafuzzaman,1 Faria Afsana,1 Nazmul Kabir Qureshi,4 Tanjina Hossain,5 M Saifuddin,6 AB Kamrul-Hasan,7 Ahmed Salam Mir8 On behalf of the BES Diabetes and COVID Task Force1Department of Endocrinology, BIRDEM General Hospital, Dhaka, Bangladesh; 2Department of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh; 3Bangladesh Endocrine Society, Dhaka, Bangladesh; 4National Healthcare Network (NHN) Uttara EC, Dhaka, Bangladesh; 5Department of Endocrinology, Green Life Medical College Hospital, Dhaka, Bangladesh; 6Department of Endocrinology, Dhaka Medical College Hospital, Dhaka, Bangladesh; 7Mymensingh Medical College Hospital, Dhaka, Bangladesh; 8Department of Endocrinology, BIHS General Hospital, Dhaka, BangladeshCorrespondence: Shahjada SelimDepartment of Endocrinology, Bangabandhu Sheikh Mujib Medical University, Shahbagh, Dhaka, 1000, BangladeshEmail selimshahjada@yahoo.comBackground: The year 2020 witnessed a largely unprecedented pandemic of coronavirus disease (COVID-19), caused by SARS COV-2. Many people with COVID-19 have comorbidities, including diabetes, hypertension and cardiovascular diseases, which are significantly associated with worse outcomes. Moreover, COVID-19 itself is allied with deteriorating hyperglycemia. Therefore, Bangladesh Endocrine Society has formulated some practical recommendations for management of diabetes and other endocrine diseases in patients with COVID-19 for use in both primary and specialist care settings.Objective: The objective of the article is to develop a guideline to protect the vulnerable group with utmost preference – the elderly and those with comorbid conditions. Therefore, to ensure the adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.Considering and Monitoring Issues: The risk of a fatal outcome from COVID-19 may be up to 50% higher in patients with diabetes than in non-diabetics.Patients with diabetes and COVID had CFR 7.3– 9.2%, compared with 0.9– 1.4% in patients without comorbidities.Diabetic ketoacidosis may be one of the causes of mortality in COVID-19.There is wide fluctuation of blood glucose in these patients, probably due to irregular diet, reduced exercise, increased glucocorticoids secretion, and use of glucocorticoids.HbA1c should be < 7.0% for the majority of the patients, this target may be relaxed in appropriate clinical settings.More emphasis should be given on day-to-day blood glucose levels. Hypoglycemia (< 3.9 mmol/l) must be avoided.Frequent monitoring of blood glucose is needed in critically ill patients.Conclusion: The fight against COVID-19 has been proven to be a challenging one. Therefore, all healthcare personnel should make the best use of updated knowledge and skills to ensure adequate protective measures and timely treatment for COVID-19 patients with diabetes, other endocrine diseases or any other comorbidities.Keywords: COVID-19, diabetes mellitus, SARS COV-2, antidiabetic medications, endocrine diseases and COVID-19, thyroid disease and COVID-19
format	article
author	Pathan F Selim S Fariduddin M Rahman MH Ashrafuzzaman SM Afsana F Qureshi NK Hossain T Saifuddin M Kamrul-Hasan AB Mir AS
author_facet	Pathan F Selim S Fariduddin M Rahman MH Ashrafuzzaman SM Afsana F Qureshi NK Hossain T Saifuddin M Kamrul-Hasan AB Mir AS
author_sort	Pathan F
title	Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
title_short	Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
title_full	Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
title_fullStr	Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
title_full_unstemmed	Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19
title_sort	bangladesh endocrine society (bes) position statement for management of diabetes and other endocrine diseases in patients with covid-19
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/c2877f5bce11418a913927b1b048f2a6
work_keys_str_mv	AT pathanf bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT selims bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT fariduddinm bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT rahmanmh bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT ashrafuzzamansm bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT afsanaf bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT qureshink bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT hossaint bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT saifuddinm bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT kamrulhasanab bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19 AT miras bangladeshendocrinesocietybespositionstatementformanagementofdiabetesandotherendocrinediseasesinpatientswithcovid19
_version_	1718389592494702592

Bangladesh Endocrine Society (BES) Position Statement for Management of Diabetes and Other Endocrine Diseases in Patients with COVID-19

Ejemplares similares